Gene therapy: Recombinant adeno-associated virus vectors

Current Cardiology Reports

Volumn 3, Issue 1, 2001, Pages 43-49

  Smith Arica, Joseph R ^a   Bartlett, Jeffrey S ^a  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS; CELLULAR IMMUNITY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; REVIEW; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION;

DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HUMANS; IMMUNITY, CELLULAR; PARVOVIRIDAE INFECTIONS; TRANSFECTION; VIRUS REPLICATION;

EID: 0035229222     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0009-x     Document Type: Article

References (62)

1. Berns KI, Pinkerton TC, Thomas GF, et al.: Detection of adenoassociated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 1975, 68:556-560.
2. Xiao X, Li J, Samulski R: Efficient long term gene transfer into muscle tissue of immunocompetent mice by adenoassociated virus vector. J Virol 1996, 70:8098-8108.
3. Berns KI, Cheung A, Ostrove J, et al.: Adeno-associated virus latent infection. In Virus Persistence. Edited by BWJ Mahy, Minson AC, Darby GK. Cambridge: Cambridge University Press; 1982:249.
4. Bartlett JS, Wilcher R, Samulski RJ: Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors, J Virol 2000, 94:2777-2785.
5. Hernandez YJ, Wang J, Kearns WG, et al.: Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999, 73:8549-8558.
6. Moskalenko M, Chen L, van Roey M, et al.: Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J Virol 2000, 74:1761-1766.
7. Li J, Dressman D, Tsao YP, et al.: rAAV vector-mediated sarcoglycan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther 1999, 6:74-82.
8. Peel AL, Zolotukhin S, Schrimsher GW, et al.: Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther 1997, 4:16-24.
9. Tenenbaum L, Jurysta F, Stathopoulos A, et al.: Tropism of AAV-2 vectors for neurons of the globus pallidus. Neuroreport 2000, 11:2277-2283.
10. Mandel RJ, Spratt SK, Snyder RO, et al.: Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997, 94:14083-14088.
11. Shen Y, Muramatsu SI, Ikeguchi K, et al.: Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000, 11:1509-1519.
12. Xiao X, McCown TJ, Li J, et al.: Adeno-associated virus (AAV) vectors antisense gene transfer in vivo decreases GABA(A) alpha1 containing receptors and increases inferior collicular seizure sensitivity. Brain Res 1997, 756:76-83.
13. Bals R, Xiao W, Sang N, et al.: Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry. J Virol 1999, 73:6085-6088.
14. Chiorini JA, Yang L, Liu Y, et al.: Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1997, 71:6823-6833.
15. Xiao W, Chirmule N, Berta SC, et al.: Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999, 73:3994-4003.
16. Zabner J, Seiler M, Walters R, et al.: Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000, 74:3852-3858.
17. Davidson BL, Stein CS, Heth JA, et al.: Recombinant adenoassociated virus type 2, 4 and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 2000, 97:3428-3432.
18. Halbert CL, Rutledge EA, Allen JM, et al.: Repeat transduction in mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000, 74:1524-1532.
19. Girod A, Ried M, Wobus C, et al.: Genetic Capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999, 5:1052-1056.
20. Wu P, Xiao W, Conlon T, et al.: Mutational analysis of the adenoassociated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000, 74:8635-8647.
21. Nakai H, Storm TA, Kay MA: Increasing the size of rAAVmediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol 2000, 18:527-532.
22. Srivastava A, Lusby EW, Berns KI: Nucleotide sequence and organization of the adeno-associated virus-2 genome. J Virol 1983, 45:555-564.
23. Atchison RW, Castro BC, Hammond WM: Adenovirus-associated defective virus particles. Science 1965, 149:754-756.
24. Schlehofer JR, Ehrbar M, zur Hausen H: Vaccinia virus, Herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus. Virology 1986, 152:110-117.
25. Yakinoglu AO, Heilbronn R, Burkle A, et al.: DNA amplification of adeno-associated virus as a response to genotoxic stress. Cancer Res 1988, 48:3123-3129.
26. Yakobson B, Koch T, Winocour E: Replication of adenoassociated virus in synchronized cells without the addition of helper virus. J Virol 1987, 61:972-981.
27. Burns KI: Parvoviridae: The viruses and their replication, In Fundamental Virology, edn 3. Edited by Fields BN, Knipe PM, Howley, et al.. New York: Raven Press; 1996:1017.
28. Samulski RJ, Zhu X, Xiao X, et al.: Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991, 10:3941-3950.
29. Ashktorab H, Srivastava A: Identification of nuclear proteins that specifically interact with the adeno-associated virus type 2 inverted terminal repeat hairpin DNA. J Virol 1989, 63:3034-3039.
30. Im D-S, Muzyczka N: The AAV origin binding protein Rep68 is an ATP-dependant site specific endonuclease with DNA helicase activity. Cell 1990, 61:447-457.
31. Young SM, McCarthy DM, Degtyareva N, et al.: Roles of adenoassociated virus Rep protein and human chromosome 19 in site specific recombination. J Virol 2000, 74:3953-3966.
32. Wu P, Phillips MI, Bui J, et al.: Adeno-associated virus vectormediated transgene integration into neurons and other nondividing cell targets. J Virol 1998, 72:5919-5926.
33. Xiao X, Li J, Samulski RJ: Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998, 72:2224-2232.
34. Gao GP, Qu G, Faust LZ, et al.: High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998, 9:2353-2362.
35. Conway JE, Rhys CM, Zolotukhin I, et al.: High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 1999, 6:986-993.
36. Clark KR, Voulgaropoulou F, Fraley DM, et al.: Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995, 6:1329-1341.
37. Anderson R, Macdonald I, Corbett T, et al.: A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease digestion and solvent extraction. J Virol Methods 2000, 85:23-34.
38. Summerford C, Samulski RJ: Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998, 72:1438-1445.
39. Qing K, Mah C, Hansen J, et al.: Human fibroblast growth factor receptor I is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999, 5:71-77.
40. Summerford C, Bartlett JS, Samulski JR: aVb5 integrin: co-receptor for adeno-associated virus type 2 infection. Nat Med 1999, 5:78-82.
41. Duan D, Yue Y, Yan Z, et al.: Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000, 105:1573-1587.
42. Hansen J, Qing K, Kwon HJ, et al.: Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000, 74:992-996.
43. Ferrari FK, Samulski T, Shenk T, et al.: Second-strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996, 70:3227-3234.
44. Kessler PD, Podsakoff GM, Chen X, et al.: Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996, 93:14082-14087.
45. Bartlett JS, Samulski RJ, McCown TJ: Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 1998, 9:1181-1186.
46. Clark KR, Sferra TJ, Lo W, et al.: Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression. J Drug Target 1999, 7:269-283.
47. Qing K, Wang X-S, Kube DM, et al.: Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2- mediated transgene expression. Proc Natl Acad Sci USA 1997, 94:10879-10884.
48. Qing K, Khuntirat B, Mah C, et al.: Adeno-associated virus type 2-mediated gene transfer: Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and in murine tissues in vivo. J Virol 1998, 72:1593-1599.
49. Mah C, Qing K, Khuntirat B, et al.: Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 1998, 72:9835-9843.
50. Fisher KJ, Alston J, Yang Y, et al.: Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997, 3:306-312.
51. Jooss K, Yang Y, Fisher KJ, et al.: Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998, 72:4212-4223.
52. Brockstedt DG, Podsakoff GM, Fong L, et al.: Induction of immunity to antigens expressed by recombinant adenoassociated virus depends upon route of administration. Clin Immunol 1999, 92:67-75.
53. Xiao X, Li J, Tsao YP, et al.: Full functional rescue of a complete (TA) in dystrophic hamsters by adeno-associated virus vectordirected gene therapy. J Virol 2000, 74:1436-1442.
54. Herzog RW, Hagstrom JN, Kung S-H, et al.: Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997, 94:5804-5809.
55. Chao H, Samulski R, Bellinger D, et al.: Persistent expression of canine factor IX in hemophilia B canines. Gene Ther 1999, 6:1695-1704.
56. Kay M, Manno CS, Ragni MV, et al.: Evidence for gene transfer and expression of factor IX in haemaphilia B patients treated with an AAV vector. Nat Genet 2000, 24:257-261.
57. Lynch CM, Hara PS, Leonard JC, et al.: Adeno-associated virus vectors for vascular gene delivery. Circ Res 1997, 80:497-505.
58. Gnatenko D, Arnold TE, Zohlotukhin S, et al.: Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells, J Investig Med 1997, 45:87-98.
59. Kaplitt MG, Xiao X, Samulski RJ, et al.: Long-term gene transfer in porcine myocardium after coronary infusion of an adenoassociated virus vector. Ann Thorac Surg 1996, 62:1669-1676.
60. Mohuczy D, Gelband CH, Phillips MI: Antisense inhibition of AT1 receptor in vascular smooth muscle cells using adeno-associated virus-based vectors. Hypertension 1999, 33:354-359.
61. Yan Z, Zhang Y, Duan D, et al.: Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA 2000, 97:6716-6721.
62. Haberman RP, McCown TJ, Samulski RJ: Novel transcriptional regulatory signals in the adeno-associated virus repeat A/D junction element. J Virol 2000, 74:8732-8739.